Characterisation of non-P-glycoprotein multidrug-resistant Ehrlich ascites tumour cells selected for resistance to mitoxantrone

Biochemical Pharmacology

Volumn 60, Issue 3, 2000, Pages 363-370

  Nielsen, Dorte ^a   Eriksen, Jens ^a   Maare, Christian ^a   Litman, Thomas ^a   Kjærsgaard, Erik ^a   Plesner, Torben ^a   Friche, Ellen ^b   Skovsgaard, Torben ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b University of Copenhagen   (Denmark)

Author keywords

Drug resistance; Mitoxantrone; Multidrug resistance associated protein; Topoisomerase II; Tumour cell lines

Indexed keywords

ADENOSINE TRIPHOSPHATASE; DAUNORUBICIN; DNA TOPOISOMERASE (ATP HYDROLYSING); ETOPOSIDE; GLYCOPROTEIN P; MITOXANTRONE; VERAPAMIL; VINCRISTINE;

ARTICLE; CELLULAR DISTRIBUTION; DRUG ACCUMULATION; DRUG MECHANISM; DRUG SENSITIVITY; EHRLICH ASCITES TUMOR; ENZYME ACTIVITY; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; TUMOR CELL CULTURE;

ADENOSINE TRIPHOSPHATASES; ANIMALS; ANTINEOPLASTIC AGENTS; ATP-BINDING CASSETTE TRANSPORTERS; BIOLOGICAL TRANSPORT; CARCINOMA, EHRLICH TUMOR; DAUNORUBICIN; DNA TOPOISOMERASES, TYPE II; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; IMMUNOASSAY; MICE; MITOXANTRONE; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; P-GLYCOPROTEIN; SUBCELLULAR FRACTIONS; TUMOR CELLS, CULTURED;

EID: 0034256969     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(00)00337-3     Document Type: Article

References (39)

1. Faulds D., Balfour J.A., Chrisp P., Langtry H.D. Mitoxantrone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the chemotherapy of cancer. Drugs. 41:1991;400-449.
2. Osheroff N., Zechiedrich E.L., Gale K.C. Catalytic function of DNA topoisomerase II. Bioessays. 13:1991;269-275.
3. Skovsgaard T., Nielsen D., Maare C., Wassermann K. Cellular resistance to cancer chemotherapy. Int Rev Cytol. 156:1994;77-157.
4. Cole S.P., Bhardwaj G., Gerlach J.H., Mackie J.E., Grant C.E., Almquist K.C., Stewart A.J., Kurz E.U., Duncan A.M., Deeley R.G. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science. 258:1992;1650-1653.
5. Izquierdo M.A., Scheffer G.L., Flens M.J., Schroeijers A.B., van der Valk P., Scheper R.J. Major vault protein LRP-related multidrug resistance. Eur J Cancer. 32A:1996;979-984.
6. Prost S. Mechanisms of resistance to topoisomerase poisons. Gen Pharmacol. 26:1995;1773-1784.
7. Nielsen D, Maare C, Eriksen J, Litman T, Friche E and Skovsgaard T, Characterisation of multidrug-resistant Ehrlich ascites tumor cells selected in vivo for etoposide resistance. In press.
8. Roed H., Christensen I.J., Vindeløv L.L., Spang-Thomsen M., Hansen H.H. Interexperiment variation and dependence on culture conditions in assaying the chemosensitivity of human small cell lung cancer cell lines. Eur J Cancer Clin Oncol. 23:1987;177-188.
9. Nielsen D., Maare C., Poulsen F., Lauridsen S.T., Skovsgaard T. Relationship between resistance, P-glycoprotein content and steady-state accumulation in five series of Ehrlich ascites tumour cell lines selected for resistance to daunorubicin. Cell Pharmacol. 1:1994;127-135.
10. Cordell J., Falini B., Erber W., Ghosh A., Abdulaziz Z., MacDonald S., Pulford K., Stein H., Mason D. Immunoenzymatic labeling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclonal anti-alkaline (APAAP) complexes. J Histochem Cytochem. 32:1984;219-229.
11. r 110,000 vesicular protein in non-P-glycoprotein-mediated multidrug resistance. Cancer Res. 53:1993;1475-1479.
12. Chomczynski P., Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem. 162:1987;156-159.
13. Danks M.K., Schmidt C.A., Cirtain M.C., Suttle D.P., Beck W.T. Altered catalytic activity of and DNA cleavage by DNA topoisomerase II from human leukemic cells selected for resistance to VM-26. Biochemistry. 27:1988;8861-8869.
14. Friche E., Danks M.K., Schmidt C.A., Beck W.T. Decreased DNA topoisomerase II in daunorubicin-resistant Ehrlich ascites tumor cells. Cancer Res. 51:1991;4213-4218.
15. Skovsgaard T. Carrier-mediated transport of daunorubicin, adriamycin, and rubidazone in Ehrlich ascites tumour cells. Biochem Pharmacol. 27:1978;1221-1227.
16. Nielsen D., Maare C., Skovsgaard T. Kinetics of daunorubicin transport in Ehrlich ascites tumor cells with different expression of P-glycoprotein. Influence of verapamil. Biochem Pharmacol. 47:1994;2125-2135.
17. Nielsen D., Maare C., Skovsgaard T. Influx of daunorubicin in multidrug resistant Ehrlich ascites tumor cells Correlation to expression of P-glycoprotein and efflux. Influence of verapamil . Biochem Pharmacol. 50:1995;443-450.
18. Borgnia M.J., Eytan G.D., Assaraf Y.G. Competition of hydrophobic peptides, cytotoxic drugs, and chemosensitizers on a common P-glycoprotein pharmacophore as revealed by its ATPase activity. J Biol Chem. 271:1996;3163-3171.
19. Chifflet S., Torriglia A., Chiesa R., Tolosa A. A method for the determination of inorganic phosphate in the presence of labile organic phosphate and high concentrations of protein Application to lens ATPases . Anal Biochem. 168:1988;1-4.
20. Harker W.G., Slade D.L., Drake F.H., Parr R.L. Mitoxantrone in HL-60 leukemia cells Reduced nuclear topoisomerase II catalytic activity and drug-induced DNA cleavage in association with reduced expression of the topoisomerase II β isoform . Biochemistry. 30:1991;9953-9961.
21. Nakagawa M., Schneider E., Dixon K.H., Horton J., Kelley K., Morrow C., Cowan K.H. Reduced intracellular drug accumulation in the absence of P-glycoprotein (mdr1) overexpression in mitoxantrone-resistant human MCF-7 breast cancer cells. Cancer Res. 52:1992;6175-6181.
22. Taylor C.W., Dalton W.S., Parrish P.R., Gleason M.C., Bellamy W.T., Thompson F.H., Roe D.J., Trent J.M. Different mechanisms of decreased drug accumulation in doxorubicin and mitoxantrone resistant variants of the MCF7 human breast cancer cell line. Br J Cancer. 63:1991;923-929.
23. Dalton W.S., Cress A.E., Alberts D.S., Trent J.M. Cytogenetic and phenotypic analysis of a colon carcinoma cell line resistant to mitoxantrone. Cancer Res. 48:1988;1882-1888.
24. Kellner U., Hutchinson L., Seidel A., Lage H., Danks M., Dietel M., Kaufmann S.H. Decreased drug accumulation in a mitoxantrone-resistant gastric carcinoma cell line in the absence of P-glycoprotein. Int J Cancer. 71:1997;817-824.
25. Futscher B.W., Abbaszadegan M.R., Domann F., Dalton W.S. Analysis of MRP mRNA in mitoxantrone-selected multidrug-resistant human tumor cells. Biochem Pharmacol. 47:1994;1601-1606.
26. Kickhoefer V.A., Rome L.H. The sequence of a cDNA encoding the major vault protein from Rattus norvegicus. Gene. 151:1994;257-260.
27. Cole S.P., Sparks K.E., Fraser K., Loe D.W., Grant C.E., Wilson G.M., Deeley R.G. Pharmacological characterization of multidrug resistant MRP-transfected human tumor cells. Cancer Res. 54:1994;5902-5910.
28. Chang X.B., Hou Y.X., Riordan J.R. ATPase activity of purified multidrug resistance-associated protein. J Biol Chem. 272:1997;30962-30968.
29. Senior A.E., Al-Shawi M.K., Urbatsch I.L. The catalytic cycle of P-glycoprotein. FEBS Lett. 377:1995;285-289.
30. Loo T.W., Clarke D.M. Rapid purification of human P-glycoprotein mutants expressed transiently in HEK 293 cells by nickel-chelate chromatography and characterization of their drug-stimulated ATPase activities. J Biol Chem. 37:1995;21449-21452.
31. Lee J.S., Scala S., Matsumoto Y., Dickstein B., Robey R., Zhan Z., Altenberg G., Bates S.E. Reduced drug accumulation and multidrug resistance in human breast cancer cells without associated P-glycoprotein or MRP overexpression. J Cell Biochem. 65:1997;513-526.
32. Yang C.H., Horton J.K., Cowan K.H., Schneider E. Cross-resistance to camptothecin analogues in a mitoxantrone-resistant human breast carcinoma cell line is not due to DNA topoisomerase I alterations. Cancer Res. 55:1995;4004-4009.
33. Miyake K., Mickley L., Litman T., Zhan Z., Robey R., Cristensen B., Brangi M., Greenberger L., Dean M., Fojo T., Bates S.E. Molecular cloning of cDNAs which are highly overexpressed in mitoxantrone-resistant cells Demonstration of homology to ABC transport genes . Cancer Res. 59:1999;8-13.
34. Lage H., Dietel M. Cloning and characterization of human cDNAs encoding a protein with high homology to rat intestinal development protein OCI-5. Gene. 188:1997;151-156.
35. Lage H., Dietel M., Fröschle G., Reymann A. Expression of the novel mitoxantrone resistance associated gene MXR7 in colorectal malignancies. Int J Clin Pharmacol Ther. 36:1998;58-60.
36. Dietel M., Seidel A. Morphologic alterations in drug sensitive vs drug resistant cells due to cytostatic application. Cancer Treat Rev. 17:(Suppl A):1990;3-10.
37. Smith P.J., Sykes H.R., Fox M.E., Furlong I.J. Subcellular distribution of the anticancer drug mitoxantrone in human and drug-resistant murine cells analyzed by flow cytometry and confocal microscopy and its relationship to the induction of DNA damage. Cancer Res. 52:1992;4000-4008.
38. Drake F.H., Hofmann G.A., Bartus H.F., Mattern M.R., Crooke S.T., Mirabelli C.K. Biochemical and pharmacological properties of p170 and p180 forms of topoisomerase II. Biochemistry. 28:1989;8154-8160.
39. Evans C.D., Mirski S.E., Danks M.K., Cole S.P. Reduced levels of topoisomerase II alpha and II beta in a multidrug-resistant lung cancer cell line. Cancer Chemother Pharmacol. 34:1994;242-248.